MANENYSEPharmaceutical PreparationsFiscal year ends December 31

Veradermics, Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$122.28+13.46 (+12.37%)

Close on Oct 19, 2026

Market cap: $4.94B
P/E (TTM): –
Dividend yield: –

Veradermics, Inc income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Research & Development	62	23
General & Administrative	10	3.50
Operating Expenses	72	27
Operating Income	-72	-27
Interest Expense	0	0.59
Interest & Investment Income	1.56	0.48
Other Non-Operating Income	2.35	0.29
Pretax Income	-70	-26
Income Tax Expense	0	0
Net Income	-70	-26
Net Income to Common	-83	-27
EPS (Basic)(per share)	-111.91	-37.05
EPS (Diluted)(per share)	-111.91	-37.05
Shares Outstanding (Basic, Weighted)(shares)	0.74	0.74
Shares Outstanding (Diluted, Weighted)(shares)	0.74	0.74

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 82.6%

Financial strength

Current ratio: 70.53
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2730.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 6.08
Dividend yield: –